Drug Trial Radar · NCT06497465
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Sep 18, 2025
Primary completion
Jan 31, 2028
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ViiV Healthcare
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy
Conditions
- Tuberculosis
- HIV
Interventions
Dolutegravir 50mg TabDrug
Participants will receive Dolutegravir 50mg
Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO]Drug
Participants will receive Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet \[DOVATO\]
Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)Drug
Participants will receive Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Among treatment-naïve participants with HIV-1 who are taking rifampin-based regimens for TB, determine the proportion with HIV-1 virologic suppression (via FDA snapshot algorithm) at 28 weeks of HIV treatment, by armTime frame: 28 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Instituto Tropical de Doenças Infecciosas Manaus
Manaus, Amazonas, Brazil · Recruiting
Universidade Federal da Bahia
Salvador, Estado de Bahia, Brazil · Recruiting
FIOCruz
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Hospital Geral de Nova Iguaçu
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
CePClin - Center for Studies and Research in Infectious Diseases Ltda
Natal, Rio Grande do Norte, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.